EIKN.US Eikon Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
5.98 USD
Close of Nov 14, 2026
5.01 17.40
Market cap
USD 324M
P/E
-
P/B
0.70x
ROE
-89.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EIKN.US undervalued?

Graham number

The Graham number of Eikon Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eikon Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Eikon Therapeutics, Inc. Common Stock yet.

Eikon Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to addre…

Full company profile